Grain News October 29th | Trifolium Biotech-B (02197.HK) announced that in Phase I clinical trials, the unadjuvanted bivalent RSV PreF trimer subunit candidate vaccine SCB-1019 (developed based on Trifolium Biotech's unique Trimer-Tag protein trimerization vaccine technology platform) was compared head-to-head with GSK's RSV vaccine AREXVY using AS01E adjuvant, obtaining more positive immunogenicity and safety data in elderly subjects.
三叶草生物-B(02197.HK)公布其二价RSV候选疫苗SCB-1019与GSK RSV疫苗AREXVY头对头比较获得积极临床数据
Adidas Biologics-B (02197.HK) announced positive clinical data from the head-to-head comparison of its bivalent RSV candidate vaccine SCB-1019 with the GSK RSV vaccine AREXVY.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated